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S252 Poster Session Ichildren and adolescents with FA who underwent allogeneic HSCT
in a single institution.
Methodology: Pts were evaluated before and 180 days after HSCT.
We evaluated the lean mass (LM) by electrical bioimpedance, nutri-
tional status by anthropometric measurements, the food intake by
a 24 hours recall, the BMD by DXA (HOLOGIC-1000) and the se-
rum 25-hydroxyvitamin D (25-OHD).
Results: Between 08/2006 and 09/2008, twenty-four patients
were included in the study. Seven pts (29%) died before
D + 180 and were excluded from this analysis. 17 pts were able
to complete this survey. The median age at admission to the
BMT Unit was 8,5ys (5-16ys), 9 pts (53%) were female and 10
pts (59%) received TCTH from unrelated donors. Most patients
(88%) developed mucositis while 7 pts (41%) developed acute or
chronic graft-versus-host disease (GVHD). Prior to HSCT, 6 pa-
tients (35%) had moderate to severe malnutrition, 10 (59%) pre-
sented short stature, 2 (12%) had low BMD for age and 11
(65%) had low vitamin D serum levels. The energy consumption
was inadequate in 6 (35%) patients and no patient had inade-
quate protein intake. At 180 days post-HSCT, six (35%) patients
had inadequate caloric intake, 1 (5%) patient had inadequate pro-
tein intake and 13 patients (76%) had low vitamin D serum
levels. A severe weight loss (greater than 5%) occurred in 6
(35%) pts, the LM decreased in 8 (47%) patients and 10
(69%) had a reduction in BMD.
Conclusion: The prevalence of weight, LM and BMD reduction
was high after six months of HSCT. The vitamin D serum levels
were low before and after HSCT. Pre-transplant nutritional care
and nutritional status monitoring of these patients are essential to
ensure proper growth and development, reducing at the most as pos-
sible the nutritional deficit during treatment.253
LONG-TERM IMPACT OF HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION ON THE NUTRITIONAL STATUS OF INFANTS
Koerich, A., Campos, D.J., Jung, R.M., Ordonez, A.M., Fortier, S.C.,
Koliski, A., Zanis Neto, J., Bonfim, C.M.S. Federal University of Parana,
Curitiba, PR, Brazil
Introduction:During the first 2 years of life the adequate nutritional
status (NS)maintenance is crucial to ensure full growth and develop-
ment.
Objectives:Evaluate changes inNS of infants undergoingHSCT in
Curitiba-Brazil during hospitalization and the long-term impact in
the NS. Analyze the nutritional therapy applied and implications
of this intervention to the patient’s outcome.
Methods: Data was collected retrospectively from medical records
considering the anthropometry at the time of hospitalization and
last outpatient visit. All pts younger than 2 years-old, transplanted
between 12/1990 and 11/2007 were included.
Results: 53pts were included, 38 (72%) were male, age was
13.56 6.2 months, 43 pts (81%) had non malignant diseases,
29 (55%) received HSCT from unrelated donors. At hospitaliza-
tion 17 pts (32%) showed mild to moderate malnutrition and 8
pts (15%) severe malnutrition. At hospital discharge, 21 pts
(40%) showed mild to moderate malnutrition and 9 pts (17%)
severe malnutrition. During hospitalization 6 pts (11%) lost 5-
10% of body weight and 3 pts (6%) lost over 10%. There was
no relationship between the baseline NS and survival, and be-
tween pathology, length of hospital stay and weight loss. 14
pts (26%) received tube feeding (TF) for 12.76 11.5 days, to
supply an average of 30.4 kcal/kg/day and 0.9 g protein/kg/day.
22 (42%) patients received parenteral nutrition (PN) for
15.76 6.1 days to supply 49.8 kcal/kg/day and 1.5 g protein/kg/
day. There was no statistical difference in the incidence of vom-
iting, diarrhea and hyperglycemia among patients who received
TF, PN or exclusively oral feeding. 30 pts survived at least
one year with a median follow up of 25406 1448 days. Age
was 6.46 3.9 years at the latest evaluation, 11 pts (33%) devel-
oped GVHD. Regarding the current NS, 19 pts (58%) had short
stature, 13 pts (39%) showed mild to moderate malnutrition and
4 pts (12%) had severe malnutrition. Analyzing the height/agecurve, 15 pts (45%) did not reach an ascendant growth curve af-
ter HSCT and 14 pts (42%) did not reach an ascendant weight/
age curve.
Conclusion:Weobserved a high prevalence ofmalnutrition prior to
HSCT and many pts persisted with long term deficits in height and
weight after transplant. The use of TF did not lead to increased gas-
trointestinal complications and could be used in order to prevent
weight loss during HSCT and diminish nutritional long term com-
plications.254
TWO YEARS WORKING: EXPERIENCE OF THE FIRST EXCLUSIVELY PEDI-
ATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PROGRAM IN COLOM-
BIA, SOUTHAMERICA
Estupinan, M., Chaparro, M. Fundacion Hospital de la Misericordia,
Bogota, Colombia
We describe the experience after two years working at the first ex-
clusively Pediatric Hematopoietic Stem cell Facility in Bogota, Co-
lombia. 26 hematopoietic stem cell transplants (HSCT) have been
done in our program. 15 (57%) allogeneic and 11(43%) autologous
HSCTs. Between allogeneic transplants all donors have been match
related donors, 53% of allogeneic transplants because acute leuke-
mia and 47% congenital or acquired bone marrow failure. Between
autologous transplants 11 patients, 6 high risk neuroblastoma (55%),
RelapsedHodgkin disease (18%), AML (9%), PNET (9%) andNon
Hodgkin lymphoma (9%). Primary results after two years are care-
fully described. Transplant related mortality is 11.5%, overall sur-
vival and event free survival are 50% and 50% respectively in
a follow up of one year. We conclude that in a pediatric population
is usual have more allogeneic transplants because of non malignant
diseases, the primary results are comparable with those for long
term experience centers given that the isolation rooms, pediatric fa-
cilities, Pediatric Intensive care in situ, and the well designed sup-
portive care strategies.255
THE IMPACT OF ROUTINE RANGE OF MOTION ASSESSMENT ON THE
EARLY IDENTIFICATION OF GRAFT VERSUS HOST DISEASE IN ALLOGE-
NEIC BONE MARROW TRANSPLANT RECIPIENTS
Hente, M.1, Chadakhtzian, A.1, Witte, B.1, Yocco, M.1, Hayashi, R.2,
Shenoy, S.2, Westfall, A.1 1St. Louis Children’s Hospital, St. Louis,
MO; 2Washington University, St. Louis, MO
Purpose:To explore the relationship betweenmonthly range ofmo-
tion assessment in allogeneic bone marrow transplant (BMT) recip-
ients and how it impacts early identification of graft versus host
disease (GvHD) and improved functional outcomes for this popula-
tion.
Abstract: Acute and chronic GvHD is prevalent in allogeneic BMT
recipients and can lead to debilitating skin and joint issues affecting
quality of life and mobility. As standard of care, these recipients re-
ceive Occupational and Physical Therapy services to combat or pre-
vent sequelae from this debilitating disorder. A recent review of
GvHD and Physical Therapy literature illustrates a lack of early
identification/prediction methods for this disorder. Very few studies
describe specific therapeutic interventions as prophylaxis utilizing
the expertise of Occupational and Physical Therapy personnel.
This institution hopes to change that and devise a method of useful
follow up.
The study population includes allogeneic BMT recipients ages
zero to 18 years old. The control group consists of the past 20 allo-
geneic bone marrow recipients and the experimental group includes
the next 20. Standard goniometry will be the assessment tool utilized
for passive range ofmotion. A baselinemeasurement will be obtained
during transplant admission, once a month for the next six months,
followed by every two to three months from month six to 24 on all
participants in the experimental group. The control group will re-
ceive standard goniometry assessment upon the diagnosis of any
GvHD, and/or at one year post transplant or with their next visit if
past one year. Functional outcomes will be measured using theWee-
FIM, which is an 18-item assessment of what a child actually does.
Poster Session I S253The experimental group will be given the WeeFIM upon admis-
sion for their allogeneic transplant and every six months thereafter,
unless they receive a diagnosis of GvHD, at which time they will
be evaluated on a bi-monthly basis. The control group will complete
the WeeFIM at their one-year post BMT (or at their next visit if
past one year).
The outcomes we anticipate achieving include: 1. Demonstrating
that range of motion assessment is a reliable indicator for early iden-
tification of skin and joint GvHD; 2. Identifying a positive relation-
ship between early intervention of GvHD and improved functional
outcomes for recipients of allogeneic BMT.256
SEVERE AND FATAL VOD FOLLOWING HEMATOPOETIC STEM CELL
TRANSPLANTATION IN TWO CHILDREN WITH SINGLE KIDNEYS
Ehlert, K., Groll, A.H., Froehlich, B., Juergens, H. University Childrens
Hospital, Muenster, Germany
Introduction: The occurrence of VOD in pediatric oncology and
HSCT has been associated with several risk factors. Impaired renal
function is frequently observed in VOD, spanning from electrolyte
disturbances and fluid retention to acute renal failure. VOD associ-
ated multi organ failure has a poor outcome.We report on two chil-
dren, 5 and 6 years old, who developed severe (1) and fatal (1) VOD,
both with a single kidney at the time of autologous HSCT for treat-
ment of stage IV neuroblastoma (NB).
Patients: Patient 1 had congenital aplasia of his right kidney. He
was diagnosed with NB in 10/2007 being treated according to
protocol NB 2004 which includes high dose chemotherapy with
melphalan, etoposide and carboplatin (MEC). There was no evi-
dence of renal impairment in previous chemotherapy courses; s-
creatinine, Ccr and urinanalysis were unremarkable. Severe VOD
peaked on day +31 of autologous HSCT with large ascites, pleu-
ral effusions and bilirubin levels of 47.3 mg/dl but with a com-
plete resolution by day +100. Patient 2 had undergone
chemotherapy, left nephrectomy and irradiation in 2007 for
treatment of wrongly diagnosed nephroblastoma in a different
country. She was correctly diagnosed with NB in 3/2008 and
treated according to protocol NB 2004. In the girl’s pre-trans-
plant evaluation, there was evidence of mild tubular renal impair-
ment, CTC grade 1; Ccr and urinanalysis proved normal.
Following autologous HSCT after MEC high dose chemother-
apy, she developed hepatic (CTC grade 3) and renal dysfunction
(CTC grade 3). Early respiratory deterioration on day +2 re-
quired mechanical ventilation and blood pressure support. She
was diagnosed with pulmonary VOD on day +34 by lung biopsy
and died on day +72. Both children had received defibrotide on
an interventional basis.
Discussion: Severity of VODwas surprising in these two children as
none had displayed any risk factors in their pre-transplant evalua-
tions. Melphalan, known for its potential to cause VOD, is fre-
quently used in pediatric high dose protocols; however, severe or
fatal courses of VOD are rarely observed. Dose reduction of melpha-
lan is recommended in renal insufficiency as its clearance may be re-
duced. Although both children had no measurable renal impairment
before high dose chemotherapy, the simultaneous use of melphalan
and carboplatin, a known nephrotoxic drug, may adversely affect
melphalan clearance in patients with a single kidney thus exposing
them to a higher risk for developing severe VOD.257
MEDICAL MANAGEMENT OF SICKLE CELL DISEASE
Vichinsky, E.P. Children’s Hospital & Research Center, Oakland, CA
Improved therapy has dramatically changed the prognosis of sickle
cell disease. Once a fatal pediatric illness, it is now a chronic adult
disease characterized by poor quality of life with end organ failure
and acute intermittent medical emergencies. Identification of high
risk patients, preventative therapies and optimal management of
complications can minimize the morbidity of sickle cell disease and
alter its progressive decline.Annual screening with transcranial Doppler enables selective
chronic transfusions to be implemented that successfully prevent
CNS injury. Early detection of asthma, pulmonary hypertension,
and hypoxia is important for improved outcomes. Acute chest syn-
drome, the most common cause of mortality, can often be pre-
vented or minimized. Renal failure may be prevented by early
treatment of proteinuria with ACE inhibitors. Avascular necrosis
of the hip may affect up to 40% of patients; early detection and
treatment with decompression coring procedures and aggressive
physical therapy may prevent or slow progression to major sur-
gery. Priapism, a morbid, often under-reported complication re-
quiring surgery, may be prevented by alpha/beta adrenergic
agonists, gonadotropin releasing hormone, and phosphodiesterase
inhibitors. Pain management in sickle cell disease remains inade-
quate, but may be improved by the day hospital model, avoidance
of hyperanalgesia syndrome, and effective use of opioids. Nutri-
tional deficiencies are common and correctable, and can improve
bone density and general health.
Transfusion therapy has seen major advances and is used in over
90% of patients by adulthood. Phenotypically matched units, access
to cytopheresis and availability of oral iron chelators have resulted in
lower alloimmunization rates and decreased iron overload. Hy-
droxyurea has globally altered the morbidity of sickle cell disease.
New hemoglobin F modulating drugs such as decitabine and short
chain fatty acids may further improve outcomes. Emerging therapies
resulting from an expanded understanding of the pathophysiology of
sickle cell disease are promising and have entered clinical trials; these
include statins, pan-selectin inhibitors, anti-coagulants, glutamine,
and nitric oxidemodifying therapies.While gene therapy has entered
Phase I trials, stem cell transplant remains the only available cure for
this disease.258
PARENTAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION FOR PA-
TIENTS WITH SEVERE APLASTIC ANEMIA: THE ST. JUDE CHILDREN’S RE-
SEARCH HOSPITAL EXPERIENCE
Kasow, K.A.1, Madden, R.2, Eldridge, P.3, Wright, N.L.3,
O’Connor, M.3, Leung, W.3, Hale, G.A.4 1University of North Carolina,
Chapel Hill, NC; 2St. Vincent Hospital, Greenbay, WI; 3St. Jude Child-
ren’s Research Hospital, Memphis, TN; 4All Children’s Hospital, St. Pe-
tersburg, FL
Patients with severe aplastic anemia (SAA) unresponsive to immu-
nosuppressive therapy (IST) require hematopoietic cell transplanta-
tion (HCT) for long-term survival. We conducted an IRB-approved
pilot study using parental donors for patients failing IST and without
an acceptable matched related or unrelated donor. The preparative
regimen consisted of OKT3 (ascending to 0.1 mg/kg/day and then
descending doses), fludarabine (160 mg/m2), thiotepa (10 mg/kg),
melphalan (120 mg/m2), and rituximab (375 mg/m2). Participants
received fresh, GM-CSF and G-CSF mobilized, CD3 depleted, pe-
ripheral blood stem cell grafts processed on the CliniMACS system;
a fixed dose of 1  105 CD3+ T-cells/kg was infused. Graft-versus-
host disease (GVHD) prophylaxis was with mycophenolate mofetil.
G-CSF was started on day +6. The primary objective was safety at
day + 100. Secondary objectives were degree of donor T-cell chime-
rism and rate of acute and chronicGVHD.Two recipients, ages 15.7
and 16.5 years, were enrolled on the study in December 2006 and
June 2007. Grafts contained 9.4-14.1 106 CD34+ cells/kg.Myeloid
engraftment occurred on days +9 and +10; platelet engraftment was
on days +16 and +18. Length of initial hospitalization was 27 and 28
days. No NCI grade 4 toxicity was observed; NCI grade 3 toxicities
included cellulitis, fever with and without neutropenia, Staphylococ-
cus aureus bacteremia, methemoglobinemia, and pancreatitis. Nei-
ther required donor lymphocytes nor stem cell boosts. Maximum
grade 2 liver and grade 1 skin acute GVHD was observed. Limited
chronic GVHD occurred: one in skin and liver, the other only in
liver. At the time of last follow-up on days +571 and +756, both par-
ticipants had 100% donor T-cell chimerism, were without signs of
SAA, and had performance scores of 100. One remains on IST for
slowly resolving skin GVHD. Overall, HCT using a reduced inten-
sity preparative regimen and an extensively T cell-depleted parental
graft is safe and results in manageable toxicities and stable engraft-
ment for recipients with SAA.
